ARCTURUS THERAPEUTICS HOLDINGS INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 100.00 thousand shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- ARCTURUS THERAPEUTICS HOLDINGS INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 100.00K shares, a 66.67% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 100.00K shares, a 80.00% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 500.00K shares, a 28.57% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 300.00K shares, a 72.73% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 600.00K shares, a 57.14% decline from fiscal 2024.
- ARCTURUS THERAPEUTICS HOLDINGS INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 1.40M shares, a 75.00% increase from fiscal 2023.
- ARCTURUS THERAPEUTICS HOLDINGS INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 800.00K shares, a 78.38% decline from fiscal 2022.
- ARCTURUS THERAPEUTICS HOLDINGS INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 3.70M shares, a 184.62% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 100.00K shares 10-Q · filed 2026-08-06 | 100.00K shares 10-Q · filed 2026-08-06 | ||||||
| 2026-03-31 | 100.00K shares 10-Q · filed 2026-05-07 | |||||||
| 2025-12-31 | 600.00K shares 10-K · filed 2026-03-03 | |||||||
| 2025-09-30 | 500.00K shares 10-Q · filed 2025-11-12 | 400.00K shares 10-Q · filed 2025-11-12 | ||||||
| 2025-06-30 | 300.00K shares 10-Q · filed 2026-08-06 | 400.00K shares 10-Q · filed 2026-08-06 | ||||||
| 2025-03-31 | 500.00K shares 10-Q · filed 2026-05-07 | |||||||
| 2024-12-31 | 1.40M shares 10-K · filed 2026-03-03 | |||||||
| 2024-09-30 | 700.00K shares 10-Q · filed 2025-11-12 | 1.10M shares 10-Q · filed 2025-11-12 | ||||||
| 2024-06-30 | 1.10M shares 10-Q · filed 2025-08-11 | 1.30M shares 10-Q · filed 2025-08-11 | ||||||
| 2024-03-31 | 1.40M shares 10-Q · filed 2025-05-12 | |||||||
| 2023-12-31 | 800.00K shares 10-K · filed 2026-03-03 | |||||||
| 2023-09-30 | 1.20M shares 10-Q · filed 2024-11-07 | 800.00K shares 10-Q · filed 2024-11-07 | ||||||
| 2023-06-30 | 1.00M shares 10-Q · filed 2024-08-05 | 800.00K shares 10-Q · filed 2024-08-05 | ||||||
| 2023-03-31 | 5.20M shares 10-Q · filed 2024-05-08 | |||||||
| 2022-12-31 | 3.70M shares 10-K · filed 2025-03-06 | |||||||
| 2022-09-30 | 500.00K shares 10-Q · filed 2023-11-14 | 507.02K shares 10-Q · filed 2022-11-09 | 700.00K shares 10-Q · filed 2023-11-14 | 650.14K shares 10-Q · filed 2022-11-09 | ||||
| 2022-06-30 | 600.00K shares 10-Q · filed 2023-08-07 | 634.31K shares 10-Q · filed 2022-08-09 | 800.00K shares 10-Q · filed 2023-08-07 | 766.59K shares 10-Q · filed 2022-08-09 | ||||
| 2022-03-31 | 800.00K shares 10-Q · filed 2023-05-09 | 824.79K shares 10-Q · filed 2022-05-09 | ||||||
| 2021-12-31 | 1.30M shares 10-K · filed 2024-03-14 | 1.26M shares 10-K · filed 2022-03-01 | ||||||
| 2021-09-30 | 1.46M shares 10-Q · filed 2022-11-09 | 1.51M shares 10-Q · filed 2022-11-09 | ||||||
| 2021-06-30 | 1.01M shares 10-Q · filed 2022-08-09 | 1.24M shares 10-Q · filed 2022-08-09 | ||||||
| 2021-03-31 | 1.32M shares 10-Q · filed 2022-05-09 | |||||||
| 2020-12-31 | 1.16M shares 10-K · filed 2022-03-01 | |||||||
| 2020-09-30 | 1.41M shares 10-Q · filed 2021-11-09 | 1.13M shares 10-Q · filed 2021-11-09 | ||||||
| 2020-06-30 | 1.51M shares 10-Q · filed 2021-08-10 | 903.95K shares 10-Q · filed 2021-08-10 | ||||||
| 2020-03-31 | 316.96K shares 10-Q · filed 2021-05-10 | |||||||
| 2019-12-31 | 138.38K shares 10-K · filed 2022-03-01 | |||||||
| 2019-09-30 | 166.92K shares 10-Q · filed 2020-11-09 | 96.61K shares 10-Q · filed 2020-11-09 | ||||||
| 2019-06-30 | 93.41K shares 10-Q · filed 2020-08-10 | 80.58K shares 10-Q · filed 2020-08-10 | ||||||
| 2019-03-31 | 67.05K shares 10-Q · filed 2020-05-08 | |||||||
| 2018-12-31 | 94.00K shares 10-K · filed 2021-03-01 | |||||||
| 2018-09-30 | 98.00K shares 10-Q · filed 2019-11-08 | 91.00K shares 10-Q · filed 2019-11-08 | ||||||
| 2018-06-30 | 81.06K shares 10-Q · filed 2019-08-14 | 87.03K shares 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |